These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1332480)

  • 1. Novel immunologic strategies in ovarian carcinoma.
    Freedman RS; Ioannides CG; Mathioudakis G; Platsoucas CD
    Am J Obstet Gynecol; 1992 Nov; 167(5):1470-8. PubMed ID: 1332480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
    Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
    Freedman RS; Platsoucas CD
    Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
    J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic therapy and immunotherapy for ovarian cancer.
    Bookman MA
    Curr Opin Oncol; 1991 Oct; 3(5):901-7. PubMed ID: 1751581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
    Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
    Mallmann P; Krebs D
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
    Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
    Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
    Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
    Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
    Chen J; Niu H; He W; Ba D
    Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
    Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS; Whiteside TL; Kanbour A; Herberman RB
    J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.